Aptinyx Inc. (APTX)
NASDAQ: APTX
· Real-Time Price · USD
0.10
0.01 (7.47%)
At close: Dec 29, 2023, 8:59 PM
7.47% (1D)
| Bid | n/a |
| Market Cap | 0 |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -29.16M |
| EPS (ttm) | -0.98 |
| PE Ratio (ttm) | -0.09795918367346938 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | n/a |
| Volume | 231,126 |
| Avg. Volume (20D) | 132,918 |
| Open | 0.09 |
| Previous Close | 0.09 |
| Day's Range | 0.09 - 0.10 |
| 52-Week Range | 0.01 - 0.72 |
| Beta | 1.22 |
About APTX
Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II/b clinical trial for treating fibromyalgia. It is also deve...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 21, 2018
Employees 12
Stock Exchange NASDAQ
Ticker Symbol APTX
Website https://www.aptinyx.com